<DOC>
	<DOCNO>NCT02063893</DOCNO>
	<brief_summary>Most study cancer stem cell ( CSC ) involve inoculation cell human tumor immunosuppressed mouse , prevent assessment immunologic interaction effect CSCs . In study , investigator examine vaccination effect produce CSC-enriched population histologically distinctmurine tumor inoculation different syngeneic immunocompetent host . Enriched CSCs immunogenic effective antigen source unselected tumor cell induce protective antitumor immunity.Immune sera CSC-vaccinated host contain high level IgG bound CSCs , result CSC lysis presence complement.CTLs generate peripheral blood mononuclear cell splenocytes harvest CSC-vaccinated host capable kill CSCs vitro . Mechanistic investigation establish CSC-primed antibody T cell capable selective target CSCs confer antitumor immunity .</brief_summary>
	<brief_title>Safety Study Cancer Stem Cell Vaccinie Treat Breast Cancer</brief_title>
	<detailed_description>To assess feasibility generate CSC-loaded DC vaccine clinical use , investigator harvest peripheral blood tumor specimen patient Breast Cancer . The investigator purify T , B cell generate DCs PBMCs Breast Cancer patient.On hand , investigator isolate ALDHhigh ALDHlow tumor cell tumor specimen Breast Cancer patient use similar protocol investigator report . Aim 1 : To demonstrate , vitro , relative cellular anti-Breast Cancer CSC immunity induce Breast Cancer CSC-DC prim cytotoxic T cell . Aim 2 : To determine , vitro , specific bind lysis Breast Cancer CSCs antibody produce purified B cell PBMCs stimulate Breast Cancer CSC-DC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>The patient ≥ 30 year age time inform consent screening obtain ; The patient one follow histologically confirm breast cancer subtypes : Estrogen receptor and/or progesterone positive tumor ; Human epidermal growth factor receptor 2 ( HER2 ) overexpressing breast cancer ; HER2negative breast cancer . The patient show normal organ function accord follow parameter ( measure within six week prior treatment allocation ) : Hemoglobin : Within normal range accord institutional standard ; Absolute leukocyte count : Within normal range accord institutional standard ; Absolute lymphocyte count : Within normal range accord institutional standard ; Platelet count : Within normal range accord institutional standard ; Alanine aminotransferase : ≤ 2.5 x Upper Limit Normal ( ULN ) ; Aspartate aminotransferase : ≤ 2.5 x ULN ; Total bilirubin : ≤ 1.5 x ULN . In case know Gilbert 's syndrome ≤ 2 x ULN ; Serum creatinine : 1.5 x ULN ; Calculated creatinine clearance : &gt; 50 mL/min . The patient inflammatory breast cancer , define clinically significant erythema breast and/or document dermal lymphatic invasion . Diagnosis establish incisional biopsy . Prior concomitant neoadjuvant antibreastcancer treatment chemotherapy , immunotherapy / biological response modifier , endocrine therapy , radiotherapy , unless authorize specifically protocol . level 3 hypertension ; severe coronary disease ; myelosuppression ; respiratory disease ; brain metastasis ; chronic infection</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>